Olanzapine is under clinical development by MedinCell and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olanzapine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
olanzapine (MDC-TJK) is under development for the treatment of schizophrenia. It is administered by subcutaneous route. It is developed as long-acting PEGylated formulation based on BEPO technology. BEPO consists of copolymers and a biocompatible solvent, where the active pharmaceutical ingredients are suspended.
MedinCell is a developer of therapeutic solutions for the healthcare market. It develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. The company’s BEPO provides a controlled release of therapeutic molecules and can be used to improve the treatment of a variety of chronic diseases or short-term illnesses. MedinCell offers peptides and proteins delivery services. MedinCell offers products for various indications including schizophrenia, pain and inflammation, depression, anaesthesia, organ transplant, and others. The company works for profit and non-profit projects and collaborates with partners including pharma, physicians, biotech firms, academics, and foundations. MedinCell is headquartered in Jacou, France.
For a complete picture of Olanzapine’s drug-specific PTSR and LoA scores, buy the report here.